Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.NS)
INR 61.89
(1.13%)
INR 61.89
(1.13%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 6.82 Million INR | -25.66% |
| 2022 | 14 Million INR | -30.59% |
| 2021 | 20.16 Million INR | -5.59% |
| 2020 | 21.36 Million INR | -27.98% |
| 2019 | 29.66 Million INR | 19.73% |
| 2018 | 24.77 Million INR | 27.11% |
| 2017 | 19.49 Million INR | 15.88% |
| 2016 | 16.81 Million INR | 41.57% |
| 2015 | 11.88 Million INR | 119.3% |
| 2014 | 5.41 Million INR | -50.47% |
| 2013 | 10.93 Million INR | 26.45% |
| 2012 | 8.64 Million INR | 211.1% |
| 2011 | 2.78 Million INR | 134.18% |
| 2010 | -8.13 Million INR | -90.9% |
| 2009 | -4.26 Million INR | -164.83% |
| 2008 | 6.57 Million INR | -1.98% |
| 2007 | 6.7 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.81 Million INR | -54.26% |
| 2023 Q4 | 3.03 Million INR | -37.28% |
| 2023 FY | 10.4 Million INR | -25.66% |
| 2023 Q2 | 3.76 Million INR | -4.37% |
| 2023 Q3 | 4.83 Million INR | 28.38% |
| 2023 Q1 | 3.93 Million INR | -0.08% |
| 2022 Q1 | 3.77 Million INR | -68.67% |
| 2022 FY | 14 Million INR | -30.59% |
| 2022 Q4 | 3.93 Million INR | 30.35% |
| 2022 Q3 | 3.02 Million INR | -7.61% |
| 2022 Q2 | 3.27 Million INR | -13.31% |
| 2021 Q1 | 4.7 Million INR | -33.35% |
| 2021 Q3 | 2.54 Million INR | -41.79% |
| 2021 FY | 20.16 Million INR | -5.59% |
| 2021 Q4 | 12.04 Million INR | 372.53% |
| 2021 Q2 | 4.37 Million INR | -6.93% |
| 2020 Q3 | 6.26 Million INR | 14.3% |
| 2020 FY | 21.36 Million INR | -27.98% |
| 2020 Q1 | 4.22 Million INR | -59.16% |
| 2020 Q2 | 5.48 Million INR | 29.81% |
| 2020 Q4 | 7.05 Million INR | 12.61% |
| 2019 Q3 | 6.65 Million INR | -6.9% |
| 2019 FY | 29.66 Million INR | 19.73% |
| 2019 Q1 | 5.52 Million INR | -40.76% |
| 2019 Q2 | 7.14 Million INR | 29.21% |
| 2019 Q4 | 10.34 Million INR | 55.48% |
| 2018 Q2 | 5.49 Million INR | 15.03% |
| 2018 FY | 24.77 Million INR | 27.11% |
| 2018 Q3 | 5.17 Million INR | -5.86% |
| 2018 Q1 | 4.77 Million INR | -55.04% |
| 2018 Q4 | 9.33 Million INR | 80.47% |
| 2017 Q1 | 1.8 Million INR | -81.83% |
| 2017 FY | 19.49 Million INR | 15.88% |
| 2017 Q4 | 10.62 Million INR | 185.79% |
| 2017 Q3 | 3.71 Million INR | 27.15% |
| 2017 Q2 | 2.92 Million INR | 61.67% |
| 2016 FY | 16.81 Million INR | 41.57% |
| 2016 Q1 | 1.59 Million INR | -86.75% |
| 2016 Q2 | 7.2 Million INR | 352.58% |
| 2016 Q3 | 7.32 Million INR | 1.69% |
| 2016 Q4 | 9.94 Million INR | 35.77% |
| 2015 Q2 | 2.98 Million INR | 70.81% |
| 2015 Q4 | 12.01 Million INR | 289.49% |
| 2015 Q3 | 3.08 Million INR | 3.35% |
| 2015 Q1 | 1.74 Million INR | 66.92% |
| 2015 FY | 11.88 Million INR | 119.3% |
| 2014 FY | 5.41 Million INR | -50.47% |
| 2014 Q4 | 1.04 Million INR | -45.63% |
| 2014 Q3 | 1.92 Million INR | -1.43% |
| 2014 Q2 | 1.95 Million INR | 296.15% |
| 2014 Q1 | 493 Thousand INR | 160.05% |
| 2013 FY | 10.93 Million INR | 26.45% |
| 2013 Q4 | -820.94 Thousand INR | -109.55% |
| 2013 Q1 | 1.62 Million INR | -65.81% |
| 2013 Q3 | 8.59 Million INR | 456.61% |
| 2013 Q2 | 1.54 Million INR | -4.75% |
| 2012 Q1 | 1.68 Million INR | 184.58% |
| 2012 FY | 8.64 Million INR | 211.1% |
| 2012 Q2 | 1.21 Million INR | -28.06% |
| 2012 Q3 | 1.01 Million INR | -15.95% |
| 2012 Q4 | 4.74 Million INR | 366.17% |
| 2011 Q3 | 1.59 Million INR | 0.0% |
| 2011 Q4 | -1.98 Million INR | -224.44% |
| 2011 FY | 2.78 Million INR | 134.18% |
| 2010 FY | -8.13 Million INR | -90.9% |
| 2009 FY | -4.26 Million INR | -164.83% |
| 2008 FY | 6.57 Million INR | -1.98% |
| 2008 Q4 | 5.68 Million INR | 0.0% |
| 2007 FY | 6.7 Million INR | 0.0% |
| 2007 Q4 | 5.4 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Sigachi Industries Limited | 579.88 Million INR | 98.824% |
| Ind-Swift Limited | 946.56 Million INR | 99.28% |
| Bajaj HealthCare Limited | 985.34 Million INR | 99.308% |
| Sakar Healthcare Limited | 204.07 Million INR | 96.658% |
| Aurobindo Pharma Limited | 55.65 Billion INR | 99.988% |
| Innova Captab Limited | 931.03 Million INR | 99.267% |
| Divi's Laboratories Limited | 14.17 Billion INR | 99.952% |
| AstraZeneca Pharma India Limited | 2.47 Billion INR | 99.724% |
| Morepen Laboratories Limited | 1.98 Billion INR | 99.657% |
| Mankind Pharma Limited | 29.27 Billion INR | 99.977% |
| Sequent Scientific Limited | 2.9 Billion INR | 99.765% |
| Wanbury Limited | 978.96 Million INR | 99.303% |
| Laurus Labs Limited | 11.9 Billion INR | 99.943% |
| Nectar Lifesciences Limited | 932.7 Million INR | 99.269% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 99.941% |
| Alembic Limited | 872.45 Million INR | 99.218% |
| Hikal Limited | 4.46 Billion INR | 99.847% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 99.957% |
| Neuland Laboratories Limited | 2.92 Billion INR | 99.767% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 99.954% |
| Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 99.985% |
| IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 99.69% |
| Themis Medicare Limited | 1.12 Billion INR | 99.394% |
| RPG Life Sciences Limited | 1.63 Billion INR | 99.583% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.995% |
| Lupin Limited | 125.09 Billion INR | 99.995% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | 99.674% |
| Wockhardt Limited | 8.48 Billion INR | 99.92% |
| Vaishali Pharma Limited | 84.02 Million INR | 91.884% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 99.778% |
| Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | 98.445% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 99.953% |
| FDC Limited | 3.49 Billion INR | 99.805% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.993% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | 98.346% |
| Eris Lifesciences Limited | 4.94 Billion INR | 99.862% |
| Venus Remedies Limited | 1.91 Billion INR | 99.644% |
| ZIM Laboratories Limited | 1.01 Billion INR | 99.327% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | 99.519% |
| Par Drugs and Chemicals Limited | 58.28 Million INR | 88.299% |
| Caplin Point Laboratories Limited | 2.17 Billion INR | 99.686% |
| Shilpa Medicare Limited | 3.33 Billion INR | 99.795% |
| Albert David Limited | 1.02 Billion INR | 99.335% |
| Ajanta Pharma Limited | 30.46 Billion INR | 99.978% |
| Hester Biosciences Limited | 908.84 Million INR | 99.25% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | 99.514% |
| Solara Active Pharma Sciences Limited | 2.55 Billion INR | 99.733% |
| Gufic Biosciences Limited | 1.18 Billion INR | 99.425% |
| Windlas Biotech Limited | 1 Billion INR | 99.322% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 99.772% |
| Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | 52.016% |
| Mangalam Drugs & Organics Limited | 162.22 Million INR | 95.796% |
| Granules India Limited | 10.31 Billion INR | 99.934% |
| Aarti Drugs Limited | 1.16 Billion INR | 99.416% |
| Bal Pharma Limited | 555.62 Million INR | 98.773% |
| Alkem Laboratories Limited | 32.83 Billion INR | 99.979% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.996% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 99.365% |
| Medicamen Biotech Limited | 335.16 Million INR | 97.965% |
| Unichem Laboratories Limited | 6.72 Billion INR | 99.899% |
| Bafna Pharmaceuticals Limited | 455.58 Million INR | 98.503% |
| Valiant Laboratories Limited | 138.02 Million INR | 95.059% |
| Orchid Pharma Limited | 800.77 Million INR | 99.148% |
| Medico Remedies Limited | 59.67 Million INR | 88.571% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 99.679% |
| Ipca Laboratories Limited | 18.98 Billion INR | 99.964% |
| Brooks Laboratories Limited | 51.18 Million INR | 86.674% |
| Syncom Formulations (India) Limited | 345.63 Million INR | 98.027% |
| Piramal Enterprises Limited | 63.65 Billion INR | 99.989% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 99.968% |
| NATCO Pharma Limited | 10.05 Billion INR | 99.932% |
| Suven Life Sciences Limited | 109.75 Million INR | 93.786% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | 85.224% |
| Strides Pharma Science Limited | 9.16 Billion INR | 99.926% |
| Indoco Remedies Limited | 12.06 Billion INR | 99.943% |
| Alpa Laboratories Limited | 127.38 Million INR | 94.646% |
| Lasa Supergenerics Limited | 291.17 Million INR | 97.658% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 99.778% |